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John A Kellum, MD, FCCM, FACP (Work Group Co-Chair),
is Professor of Critical Care Medicine, Medicine, Bio-
engineering and Clinical and Translational Science, and Vice
Chair for Research within the Department of Critical Care
Medicine at the University of Pittsburgh. In addition, he is
the Director of the Program on Bioengineering and Organ
Support for the CRISMA (Clinical Research Investigation
and Systems Modeling of Acute Illness) Center at the
University of Pittsburgh.
Dr Kellum is actively involved in education, research, and
administration. His research interests span various aspects
of critical-care medicine, but center in critical-care nephro-
logy, sepsis, multiorgan failure, and clinical epidemiology,
including consensus development and research methodology.
He has authored more than 300 publications and served as
editor and contributor to recent texts including Continuous
Renal Replacement Therapy, Critical Care Nephrology, and
Management of Acute Kidney Problems. Dr Kellum has won
several awards for teaching and has given more than 400
seminars and invited lectures worldwide related to his
research.
Advisor/Consultant: Abbott; Alere; Astute Medical; Baxter;
CytoSorbents; EBI; Eli Lilly; Fresenius; Gambro; Siemens;
Spectral Diagnostics
Speaker: Baxter; Fresenius; Gambro
Grant/Research Support: Astute Medical; Baxter; CytoSorbents;
Gambro
Norbert Lameire, MD, PhD (Work Group Co-Chair), is
Professor of Internal Medicine and former Chief of Renal
Division at the University of Ghent where he also received his
medical degree and PhD. Dr Lameire’s interests include basic
research topics such as renal circulation in experimental ARF
and peritoneal circulation, as well as clinical topics spanning
clinical ARF, PD, and organizational and economic aspects
of chronic RRT and transplantation. He currently oversees
the worldwide continuing medical education programs of
COMGAN of the International Society of Nephrology, and
serves as current Editor-in-Chief for Acta Clinica Belgica
and is emeritus Editor-in-Chief for Nephrology Dialysis
Transplantation. For his activities in the Renal Sister Program
of the International Society of Nephrology and his leadership
of the Renal Disaster Relief Task Force, he was awarded
Doctor Honoris Causa at the Kaunas Medical Academy in
Lithuania and an honorary membership of the International
Society of Nephrology (ISN). Dr Lameire also received the
Garabed Eknoyan Award from the NKF (USA) in 2007 for his
continuing work to improve dialysis therapy and PD, and his
contributions to improving and implementing KDOQI
Guidelines. He also served as the KDIGO Co-Chair from
2004 to 2007.
Dr Lameire reported no relevant financial relationships.
Peter Aspelin, MD, PhD, received his basic training in
radiology at Malmo¨ University Hospital (Lund University)
and was Associate Professor there for 13 years. In 1989 he
became Professor and Chairman of the Department of
Radiology at Karolinska Institutet, Huddinge University
Hospital. Professor Aspelin was Vice Dean of the Medical
School at Karolinska Institutet from 1993 to 1995 and served
as Vice President at the institution from 1995 to 2001. He was
also Head of Research & Development at Huddinge
University Hospital in 2002 and Vice Chairman of Research
& Development at the Karolinska University Hospital. Other
notable accomplishments also include his roles as President
for the Scientific Board of the Swedish Council of Technology
Assessment in Health Care (1999–2005); Chairman of the
Swedish Society of Medical Radiology (2003–2005); and past
Vice Chairman and current Chairman of the Swedish
Medical Association.
Professor Aspelin has conducted research on contrast
media since 1972 when he studied under the tutelage of
Professor Torsten Alme´n. He has written more than 170
scientific publications to date and his primary research
centers on the development of nonionic contrast media and
the examination of their effects on medical imaging and
patient safety.
Speaker: GE Healthcare
Expert witness: GE Healthcare
Rashad S Barsoum, MD, FRCP, FRCPE, is Emeritus
Professor of Medicine at Cairo University and current
Chairman of Cairo Kidney Center and Medical Sector
Committee for Supreme Council for Egyptian Universities.
He received his medical degree from Cairo University, where
he also completed his fellowship in nephrology in 1967.
Dr Barsoum has been a primary investigator in clinical trials
involving the study of immunosuppression agents in kidney
transplantation and treatment of HCV infection in dialysis
patients. He has also authored more than 200 journal articles
and book chapters and currently serves as Associate Editor
for Nephron Clinical Practice and editorial board member for
American Journal of Kidney Diseases. Dr Barsoum is also
active in numerous medical societies, having served as Past
President for the Arab Society of Nephrology and Renal
Transplantation and Egyptian Society of Nephrology. Among
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his noted achievements include the International Award from
the NKF (USA), the Roscoe Robinson Award from the
International Society of Nephrology, and the Distinguished
Researcher Award from Cairo University.
Advisor/Consultant: Wyeth
Speaker: Amgen; B. Braun; Fresenius; Janssen Cilag;
Novartis; Roche; Wyeth
Emmanuel A Burdmann, MD, PhD, is Head of Intensive Care
Unit and Associate Professor, Division of Nephrology at
University of Sa˜o Paulo Medical School. He received his
medical degree from the University of Sa˜o Paulo, where he also
completed his fellowship. He was the Past President of the
Latin American Society of Nephrology and Hypertension and
current President of Brazilian Society of Nephrology. Dr
Burdmann has authored over 150 journal articles and book
chapters and is currently on the editorial boards of Clinical
Journal of the American Society of Nephrology, Clinical
Nephrology, Kidney International, Nephrology Dialysis Trans-
plantation, and Nephron Clinical Practice. He is also a member
of numerous professional societies and has served on the
Council of the International Society of Nephrology and
KDIGO Board. In addition to his research interest in AKI,
Dr Burdmann is also a coinvestigator in the TREAT study.
Dr Burdmann reported no relevant financial relationships.
Stuart L Goldstein, MD, is Professor of Pediatrics and Director,
Center for Acute Care Nephrology at Cincinnati Children’s
Hospital Medical Center. He received his medical degree from
Columbia University and completed both clinical and research
fellowships in pediatric nephrology at the Children’s Hospital
in Boston, Massachusetts. Dr Goldstein is a member of the
American Academy of Pediatrics, the American Society of
Nephrology, the International Pediatric Nephrology Asso-
ciation, the American Society of Pediatric Nephrology, the
International Society of Nephrology, and the Society for
Pediatric Research. In addition, he is Chairman of the Medical
Advisory Committee to the FORUM of ESRD Networks and a
member of the Medical Review Board for the ESRD Networks
9 and 10, is the Pediatric Nephrologist Representative for the
International Society of Nephrology Commission of Acute
Renal Failure, and has been elected to the Council of the
American Society of Pediatric Nephrology. Dr Goldstein has
developed and validated the pediatric modified RIFLE
(pRIFLE) AKI criteria, is Founder and Principal Investigator
for the Prospective Pediatric Continuous Renal Replacement
Therapy (ppCRRT) Registry Group, and has evaluated novel
urinary AKI biomarkers in the pediatric critical care setting. He
has written over 110 journal articles and contributed book
chapters to numerous texts including, Critical Care Nephrology,
Evidence-Based Nephrology, Handbook of Dialysis Therapy,
Management of Acute Kidney Problems, Pediatric Critical Care,
Pediatric Nephrology, and Pediatric Nephrology in the ICU.
Advisor/Consultant: Baxter; Gambro
Speaker: Gambro
Grant/Research Support: Amgen; Baxter; Gambro
Charles A Herzog, MD, is Director of the Cardiovascular
Special Studies Center, United States Renal Data System
(USRDS). An investigator at the USRDS since 1999,
Dr Herzog has been a cardiologist at Hennepin County
Medical Center (HCMC) in Minneapolis and a member of the
University of Minnesota faculty for 27 years. He has been
a professor of medicine at the University of Minnesota since
2004 and the cardiology consultant to the ESRD program
(dialysis and renal transplant) at HCMC since 1985. He
founded the program in interventional cardiology and served
as the director of the cardiac catheterization laboratory at
HCMC from 1985 to 1991. Since 1997, Dr Herzog has been
the director of the cardiac ultrasound laboratory at HCMC.
He participated in the development of the National Kidney
Foundation’s K/DOQI Clinical Practice Guidelines for Cardio-
vascular Disease in Dialysis Patients, and co-chaired the 2010
KDIGO Controversies Conference, ‘‘Cardiovascular Disease in
CKD: What is it and What Can We Do About It?’’ The author
or co-author of more than 100 published papers and reviews,
Dr Herzog has served on the Editorial Board for the American
Heart Journal since 2005 and as liaison editor (cardiology) for
Nephrology Dialysis Transplantation since 2007. His areas of
research and special interests include cardiac disease and
chronic kidney disease, and echocardiography.
Advisor/Consultant: Abbott; Affymax; Amgen; CorMedix;
FibroGen; Fresenius
Board of Trustees: Roche Foundation for Anemia Research
Honorarium: UpToDate
Grant/Research Support: Johnson & Johnson; National Institutes
of Health
Equity Interest: Boston Scientific; Cambridge Heart; Johnson
& Johnson; Merck
Michael Joannidis, MD, is Associate Professor in Medicine
and serves as Director of the Medical Intensive Care Unit,
Dept. Internal Medicine I at Medical University Innsbruck in
Austria. He is a certified specialist in critical-care medicine,
nephrology, and cardiology, and his research interests cover
several aspects of critical-care medicine with a major focus on
AKI, renal tubular epithelial pathophysiology, RRT, and sepsis.
Dr Joannidis currently serves as chair of the section Acute
Kidney Injury of the European Society of Intensive Care
Medicine (ESICM), President of the Austrian Society of
Medical and General Intensive Care Medicine (OEGIAIM)
and associate editor of Intensive Care Medicine.
Speaker: Baxter; Fresenius; Gambro
Andreas Kribben, MD, is Professor of Medicine and Head of
the Department of Nephrology at the University Hospital
Essen at the University of Duisburg-Essen. He received his
medical degree at the Johann-Wolfgang Goethe University
Frankfurt, Germany in 1983. Dr Kribben was trained in
Internal Medicine and Nephrology at the Department of
Nephrology of the University Hospital Klinikum Steglitz,
Free University of Berlin, Germany and at the University
Hospital Essen, University Duisburg-Essen, Germany. From
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1990 to 1993, he was a research fellow at the Renal Division
of the University of Colorado Health Sciences Centre in
Denver, Colorado, USA. His major scientific interests include
all aspects of AKI, CRF, as well as transplantation and
hypertension.
Dr Kribben is member of numerous professional organi-
zations, including the International Society of Nephrology,
the American Society of Nephrology, the European Dialysis
and Transplantation Association, and he is a member of the
Board of Directors of the German Society of Nephrology.
He is an editorial member of Clinical Nephrology and served
as subject editor of Nephrology Dialysis Transplantation.
Dr Kribben is also a member of the World Health
Organization Work Group for the 11th revision of ICD.
Advisor/Consultant: Roche; Shire; Teva
Speaker: Amgen; Apherese ForschungsInstitut; Baxter;
Bayer-Schering; Berlin-Chemie; Fresenius; GE Healthcare;
Genzyme; Roche; Shire
Grant/Research Support: B. Braun; Biosite; Fresenius;
Koehler; Roche; Teva
Andrew S Levey, MD, is Dr Gerald J. and Dorothy R.
Friedman Professor of Medicine at Tufts University School
of Medicine, Chief of the William B. Schwartz, MD Division
of Nephrology at Tufts Medical Center, Senior Scientist at
the US Department of Agriculture Human Nutrition
Research Center on Aging at Tufts University, and Professor,
Clinical Research at the Sackler School of Graduate
Biomedical Sciences at Tufts University. His research is
mainly in the areas of epidemiology of CKD and cardio-
vascular disease in CKD, controlled trials to slow the
progression of CKD, clinical assessment of kidney function,
assessment and improvement of outcomes in dialysis and
transplantation, and clinical practice guideline develop-
ment and implementation. Dr Levey is currently Program
Director for an NIDDK-funded clinical research training
program, ‘‘Clinical Trials, Epidemiology and Outcomes
Research in Nephrology’’. He is also the Director of the
Tufts Center for Guideline Development and Implementation
and Editor of the American Journal of Kidney Disease.
Dr Levey is past Chair of the NKF’s Task Force on
Cardiovascular Disease in Chronic Renal Disease, KDOQI
Work Group on Chronic Kidney Disease: Evaluation,
Classification and Stratification, and KDOQI Work Group
on Hypertension and Antihypertensive Agents in Chronic
Kidney Disease.
Grant/Research Support: Amgen; National Institutes of
Health; National Kidney Foundation
Alison M MacLeod, MBChB, MD, FRCP London and
Edinburgh, is Professor in the Department of Medicine
and Therapeutics at the University of Aberdeen Medical
School, UK. She completed her fellowship at the Royal
Colleges of Physicians of London and Edinburgh, and has
interests in epidemiology of CKD, AKI, and evidence based
medicine in nephrology. Her research group also conducts
systematic literature reviews and she is a member of the
Editorial Board of the Cochrane Review Group. Dr MacLeod
is a current committee member of the European Renal
Registry Executive Committee, Anemia Management in
Chronic Kidney Disease–National Institute for Health and
Clinical Excellence, Scientific Committee, and European
Renal Association Congress. In addition, she is Chairman
of the Scottish Intercollegiate Guidelines Network, Diagnosis
and Management of Chronic Renal Failure and was a
member of the Executive Committee of KDIGO.
Dr MacLeod reported no relevant financial relationships.
Ravindra L Mehta, MD, FACP, FASN, FRCP, is Professor
of Medicine in the Division of Nephrology and Associate
Chair for Clinical Research in the Department of Medicine
at the University of California, San Diego (UCSD) where
he directs the Acute Dialysis Program and the UCSD
CREST and Masters in Clinical Research Program. He
received the M.B.B.S. degree (1976) from the Government
Medical School in Amritsar, India, and the M.D. (1979)
and D.M. (1981) degrees from the Post-Graduate Institute
of Medical Education and Research in Chandigarh, India.
He subsequently completed a nephrology fellowship at
the University of Rochester in Rochester, New York and
obtained his boards in internal medicine (1986) and
Nephrology (1988). He has been on the faculty at UCSD
since 1988.
Dr Mehta is an internationally recognized expert in the
field of ARF and has directed several clinical studies in the
management of patients with kidney disease including
comparing different dialytic modalities in the treatment of
AKI, conducting large multicenter observational studies of
AKI with the PICARD group, evaluating different predictive
models for outcomes in AKI, investigating the role of
cytokine removal by dialysis membranes in sepsis and AKI,
and evaluating techniques for determining the amount of
excess fluid in dialysis patients. In addition to his clinical and
research activities, he has worked with the American Society
of Nephrology, NKF, Society of Critical Care Medicine, and
the International Society of Nephrology in developing
courses for fellows and practicing physicians in clinical
nephrology and dialysis techniques. Dr Mehta chairs the
annual International Conference on CRRT that is now in its
15th year and he is also the Chair of the International Society
of Nephrology Committee on AKI, founding member of the
ADQI and AKIN. He has authored over 150 scientific articles,
papers and book chapters, and has been actively involved in
resident and scholar teaching. He won the house staff
teaching award on four occasions and was awarded School of
Medicine Faculty teaching award in 2003. He has been
recognized as one of the Best Doctors in San Diego and the
USA. In 2008, he was recognized by the American
Nephrologists of Indian Origin for his achievements in
nephrology. In March 2009, he was elected as a Fellow of the
Royal College of Physicians in the UK. Over the course of his
academic career, he has trained over 50 postdoctoral fellows
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in nephrology, of whom 15 have carried out their research
projects with him.
Advisor/Consultant: Astute Medical; Eli Lilly; Takeda
Speaker: Baxter; Gambro
Grant/Research Support: Eli Lilly
Patrick T Murray, MD, FASN, FRCPI, FJFICMI, is a
nephrologist and clinical pharmacologist at the Mater
Misericordiae University Hospital and University College
Dublin, Ireland. Dr Murray received his medical education at
University College Dublin, Ireland and following his intern-
ship at the Mater Misericordiae University Hospital in
Dublin, he completed his residency in internal medicine
at Hennepin County Medical Center in Minneapolis, Minnesota,
USA and fellowship training programs in nephrology, critical
care medicine, and clinical pharmacology at the University of
Chicago Hospitals in Chicago, Illinois, USA.
Dr Murray is board-certified in internal medicine,
nephrology, critical care medicine, and clinical pharmacology
and practiced as an intensivist, nephrologist, and clinical
pharmacologist at the University of Chicago Hospitals from
1996 to 2008, serving as the fellowship training program
director in nephrology and also directing the Acute Dialysis
Service. Since 2008, he has been the Professor of Clinical
Pharmacology at University College Dublin, and a Con-
sultant in Nephrology & Clinical Pharmacology at the Mater
Misericordiae University Hospital. Dr Murray has published
extensively with contributions in numerous books inclu-
ding, Critical Care Nephrology, Evidence-Based Nephrology,
Evidence-Based Practice of Critical Care, and Intensive Care in
Nephrology. He has a long-standing interest in research and
education to improve the prevention, diagnosis, and therapy
of AKI.
Advisor/Consultant: Abbott; Alere; AM Pharma; Argutus
Medical; FAST Diagnostics; Reata; Sanofi-Aventis
Grant/Research Support: Abbott; Alere; Argutus Medical
Saraladevi Naicker, MBChB, MRCP, FRCP, FCP (SA), PhD,
is currently Academic Head of the Department of
Internal Medicine and Professor of Renal Medicine and head
of the Division of Nephrology at the University of the
Witwatersrand in Johannesburg. She completed her under-
graduate and postgraduate medical training primarily at the
University of Natal in Durban, South Africa and spent short
periods training in nephrology at the Universities of the
Witwatersrand, Johannesburg and Newcastle on Tyne in the
UK. She currently chairs the Postgraduate (Higher Degrees)
Committee of the Faculty of Health Sciences at the University
of the Witwatersrand and is a member of the Council of the
College of Physicians of the Colleges of Medicine of South
Africa. She is also a Council member of the International
Society of Nephrology (ISN) and chairs its Education
Committee.
Dr Naicker was the recipient of the Philip Tobias/Convo-
cation Distinguished Teachers Award at the University of the
Witwatersrand in 2006, the International Distinguished
Medal of NKF of the USA in 2005 and was awarded the
prestigious Roscoe Robinson award for nephrology education
by the ISN at its World Congress in Milan in May 2009. She
has hosted the nephrology training of ISN Fellows from
Ethiopia, Nigeria, Botswana, Tanzania, Rwanda, Kenya and
Zambia as well as ISPD trainees from Nigeria and Tanzania.
During her period as Chair of the Africa Committee of ISN
COMGAN from 2000 to 2007, she made site visits and
participated in continuing medical education programs in
many African countries. Her research interests include areas
related to HIV and kidney disease, prevention of CKD, CVD
in renal disease, and medical education.
Advisor/Consultant: Amgen; Novartis; Roche
Steven M Opal, MD, is Professor of Medicine at The Warren
Alpert Medical School of Brown University and Chief of the
Infectious Disease Division, Memorial Hospital of Rhode
Island. He received his medical degree from Albany Medical
School, Albany, New York and completed his fellowship
training in infectious diseases at Walter Reed Army Medical
Center in Washington, DC. Dr Opal is a member of
numerous national and international committees including,
International Steering Committee for Sepsis Clinical Trials;
Steering Committee FDA Meta-analysis Committee on
Sepsis; International Endotoxin Society; and International
Sepsis Forum. He has written extensively with over 300
publications and has given more than 100 invited presenta-
tions. Dr Opal currently serves on the editorial boards of
Advances in Sepsis, Critical Care Forum, Current Opinion in
Critical Care, and Shock. In recognition for his work, he was
awarded the Brown Medical School Infectious Disease
Fellowship Teacher of the Year Award in 2008 and was
acknowledged in Best Doctors in America from 2003 to 2009.
Dr Opal reported no relevant financial relationships.
Franz Schaefer, MD, is Professor of Pediatrics and Chief of
the Pediatric Nephrology Division at Heidelberg University
Hospital. Dr Schaefer received his M.D. at Wu¨rzburg
University Medical School and performed research scholar-
ships at the Institute of Child Health, London, University of
Virginia, and Stanford University. His research interests
include topics on physiopathology of growth failure,
cardiovascular and endocrine disorders in CKD and the role
of genetic abnormalities in congenital kidney disorders. In
clinical research, he conducted numerous collaborative
clinical trials and established several international consortia
such as the the European Study Group on Progressive CKD
in Children, the International Pediatric Peritoneal Dialysis
Network, and the PodoNet Registry for Steroid Resistant
Nephrotic Syndrome. Dr Schaefer has published over 280
articles and book chapters, and co-edited the standard
textbooks Comprehensive Pediatric Nephrology and Pediatric
Dialysis. He received several prestigious awards for innovative
research including the Recklinghausen Prize and the IBM
Faculty Award. Dr Schaefer is a current council member of
the International Pediatric Nephrology Association and the
Kidney International Supplements (2012) 2, 116–121 119
b iograph i c and d i sc losure in fo rmat ion
International Society of Peritoneal Dialysis. He is a member
of several editorial boards and serves as Section Editor for
Nephrology Dialysis Transplantation and Pediatric Nephrology.
Dr Schaefer reported no relevant financial relationships.
Miet Schetz, MD, PhD, graduated from the faculty
of Medicine of the Catholic University of Leuven, Belgium,
after which she specialized in anesthesiology and later in
intensive care medicine. Since 1981 she is staff member of
the department of Intensive Care Medicine at the University
Hospital Leuven (Chair: Greet Van den Berghe) and has
been Associate Professor at the Catholic University Leuven
since 2000. Dr Schetz completed her PhD thesis on the
subject, ‘‘The Hemostatic System and Continuous Renal
Replacement Therapy: Mutual Effects’’. Her main field of
interest is AKI and its treatment, on which she published
several articles.
Grant/Research Support: Gambro
Shigehiko Uchino, MD, PhD, is Associate Professor and Staff
Intensivist in the Department of Anesthesiology at Jikei
University School of Medicine in Tokyo, Japan. He received
his medical degree from Tokyo Medical and Dental
University and his PhD from Jikei University School of
Medicine. Dr Uchino is a member of the Japanese Society of
Intensive Care Medicine, Japanese Association for Acute
Medicine, Society of Critical Care Medicine, and the
European Society of Intensive Care Medicine. In addition
to serving as a reviewer for numerous journals, he has written
book chapters in recent texts such as Critical Care Nephrology,
Evidence-Based Practice of Critical Care, and Intensive Care
in Nephrology. Dr Uchino is also a coinvestigator in the
BEST Kidney study.
Dr Uchino reported no relevant financial relationships.
KDIGO CHAIRS
Kai-Uwe Eckardt, MD, is Professor of Medicine and Chief
of Nephrology and Hypertension at the University of
Erlangen—Nuremberg, Germany. He received his MD from
the Westfa¨lische Wilhelms-Universita¨t Mu¨nster, Germany. In
1993, following postgraduate training in internal medicine,
pathology and physiology, he was appointed Assistant
Professor of Physiology at the University of Regensburg,
Germany. Subsequently, he continued his training in internal
medicine and nephrology at the Charite´, Humboldt Uni-
versity in Berlin, where he was appointed Associate Professor
of Nephrology in 2000. His major scientific interests are in
the molecular mechanisms and physiological/pathophysio-
logical relevance of oxygen sensing and the management of
anemia. As such, he has contributed to the development of
the European Best Practice Guidelines for Anemia Manage-
ment and participated in the CREATE and TREAT studies.
Professor Eckardt is subject editor of Nephrology Dialysis
Transplantation and serves on the editorial board of several
other journals. He has also authored book chapters and most
recently served as a Co-Editor of the text, Studies on Renal
Disorders. Dr Eckardt is a member of the executive committee
of KDIGO.
Advisor/Consultant: Affymax; Amgen; Hexal Sandoz;
Johnson & Johnson; Roche
Speaker: Amgen; Janssen Cilag; Johnson & Johnson; Roche
Grant/Research Support: Roche
Bertram L Kasiske, MD, is Professor of Medicine at the
University of Minnesota, USA. He received his medical
degree from the University of Iowa and completed his
Internal Medicine residency and fellowship training in
Nephrology at Hennepin County Medical Center where he
is currently Director of Nephrology.
Dr Kasiske is former Deputy Director of the United States
Renal Data System and former Editor-in-Chief of The
American Journal of Kidney Diseases. He has served as
Secretary/Treasurer and on the Board of Directors of the
American Society of Transplantation, and on the Organ
Procurement and Transplantation Network/United Network
of Organ Sharing Board of Directors, and the Scientific
Advisory Board of the National Kidney Foundation. He is
currently serving on the Board of Councilors of the
International Society of Nephrology. He is the Principal
Investigator for a National Institutes of Health-sponsored,
multi-center study of long term outcomes after kidney
donation. He is the Director of the Scientific Registry of
Transplant Recipients. He has over 160 scientific publications
in major peer reviewed journals, and 230 review articles,
editorials and textbook chapters. Dr Kasiske is also a recipient
of the NKF’s Garabed Eknoyan Award in 2003.
Advisor/Consultant: Litholink
Grant/Research Support: Bristol-Myers Squibb; Merck-Schering
Plough
EVIDENCE REVIEW TEAM
Katrin Uhlig, MD, MS, is the Director, Guideline Develop-
ment at the Tufts Center for Kidney Disease Guideline
Development and Implementation, Boston, MA, Associate
Professor of Medicine at Tufts University School of Medicine,
and a staff nephrologist at Tufts Medical Center. Dr Uhlig
completed her training in internal medicine, nephrology, and
rheumatology in Germany (Aachen University Hospital and
Munich University Hospital) and the USA (Georgetown
University Medical Center and Tufts Medical Center). Since
2001, she has been participating in or directing the evidence
review for KDOQI and KDIGO guidelines. In 2005, she
co-chaired the KDIGO Evidence Rating Group to develop
a consensus on grading of KDIGO guidelines. From 2006
to 2007, she served as Co-Editor of the American Journal
of Kidney Diseases. Her focus in teaching and research is in
evidence-based medicine, systematic review, clinical practice
guideline development, and critical literature appraisal.
Dr Uhlig reported no relevant financial relationships.
Jose Calvo-Broce, MD, MS, served as a research fellow at the
Tufts Center for Kidney Disease Guideline Development and
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Implementation in Boston, MA and participated in the
conduct of systematic reviews and critical literature apprai-
sals for this guideline. Dr Calvo-Broce was recently awarded
a Master of Science in Clinical Research for his thesis
on ‘‘Hospital-Acquired AKI: An Analysis of Nadir-to-Peak
Serum Creatinine Increments Stratified by Baseline Estimated
GFR’’.
Dr Calvo-Broce reported no relevant financial relationships.
Aneet Deo, MD, MS, served as a research fellow at the
Tufts Center for Kidney Disease Guideline Development
and Implementation in Boston, MA. She participated in the
conduct of systematic reviews and critical literature appraisals
for this guideline. Dr Deo was awarded a Master of Science
in Clinical Research for her thesis on ‘‘Loss to Analysis in
Randomized Controlled Trials of Chronic Kidney Disease’’.
Dr Deo reported no relevant financial relationships.
Amy Earley, BS, is a project coordinator at the Tufts Center
for Kidney Disease Guideline Development and Implementa-
tion in Boston, MA. She assists in the development of clinical
practice guidelines and conducts systematic reviews and
critical literature appraisals.
Ms Earley reported no relevant financial relationships.
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